IHE Performance — iShares U.S. Pharmaceuticals ETF
Data updated: 2026-08-24
IHE returned +17.50% year to date and +53.73% over one year to Jun 2026. Annualised returns are +20.36% over 3 years and +11.77% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $174, against $138 for the category, and to $154 over one year, against $137. Volatility over the past three years was 15.84% a year. In the 12 months to Jun 2026 the fund took in a net $280.2M, and assets reached $1.14B.
IHE Growth of $100
What $100 invested in iShares U.S. Pharmaceuticals ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | IHE | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $154 | $137 |
| 3 years (Jul 2023 – Jun 2026) | $174 | $138 |
| 5 years (Jul 2021 – Jun 2026) | $174 | $121 |
| Since data start (Jul 2019 – Jun 2026) | $221 | $182 |
IHE Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +17.50% |
| 1 year | +53.73% |
| 3 years (annualised) | +20.36% |
| 5 years (annualised) | +11.77% |
IHE Annual Returns
Calendar-year total returns of iShares U.S. Pharmaceuticals ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +17.50% |
| 2025 | +31.74% |
| 2024 | +8.09% |
| 2023 | +0.99% |
| 2022 | −4.78% |
| 2021 | +12.84% |
| 2020 | +13.83% |
| 2019 (Jul–Dec) | +6.98% |
IHE Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.2% | +6.0% | −5.3% | +1.1% | +4.7% | +8.2% | — | — | — | — | — | — |
| 2025 | +5.9% | +4.6% | −2.5% | −3.1% | −4.7% | +1.1% | +0.3% | +8.3% | +2.5% | +4.6% | +12.4% | 0.0% |
| 2024 | +3.0% | +6.7% | +0.5% | −5.6% | +2.6% | +1.4% | +3.0% | +6.7% | −2.7% | −2.1% | 0.0% | −4.8% |
| 2023 | −0.3% | −5.2% | +0.1% | +3.4% | −5.3% | +4.6% | +1.8% | +4.0% | −6.2% | −5.4% | +4.8% | +5.9% |
| 2022 | −4.5% | −3.5% | +6.1% | −3.2% | +3.5% | −1.0% | −0.7% | −7.6% | −3.2% | +6.9% | +3.7% | −0.2% |
| 2021 | +0.1% | −0.6% | −0.3% | +1.0% | +2.9% | +1.1% | +3.3% | +0.7% | −4.8% | +2.8% | −0.5% | +7.0% |
| 2020 | −0.5% | −9.3% | −6.3% | +13.0% | +3.2% | −2.0% | +2.6% | +6.0% | −1.9% | −2.3% | +7.2% | +5.3% |
| 2019 | — | — | — | — | — | — | −4.2% | −3.5% | +0.7% | +4.4% | +3.5% | +6.3% |
IHE Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 15.84%
- 3-year Sharpe ratio: 1.00 (vs 4.5% risk-free rate)
- Best month: +12.36% (Nov 2025)
- Worst month: −6.18% (Sep 2023)
IHE Fund Flows
Monthly money in and out of iShares U.S. Pharmaceuticals ETF, from SEC Form N-PORT.
- 12-month net flow: $280.2M
- 12-month gross sales (incl. reinvestments): $554.7M
- Sales ÷ redemptions: 2.02×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $162.4M | $14.0M | $148.4M |
| May 2026 | $8.9M | $84.1M | −$75.1M |
| Apr 2026 | $13.0M | $78.2M | −$65.2M |
| Mar 2026 | $13.3M | $17.9M | −$4.6M |
| Feb 2026 | $35.8M | $0 | $35.8M |
| Jan 2026 | $118.6M | $17.1M | $101.6M |
| Dec 2025 | $71.6M | $21.1M | $50.5M |
| Nov 2025 | $120.1M | $7.8M | $112.3M |
| Oct 2025 | $3.7M | $0 | $3.7M |
| Sep 2025 | $7.0M | $17.5M | −$10.4M |
| Aug 2025 | $0 | $3.5M | −$3.5M |
| Jul 2025 | $0 | $13.4M | −$13.4M |
IHE Assets Under Management
Net assets of iShares U.S. Pharmaceuticals ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $1.14B |
| 2026-03-31 | $1.00B |
| 2025-12-31 | $847.73M |
| 2025-09-30 | $580.76M |
| 2025-06-30 | $550.45M |
| 2025-03-31 | $617.35M |
| 2024-12-31 | $610.57M |
| 2024-09-30 | $660.08M |
| 2024-06-30 | $683.48M |
| 2024-03-31 | $658.75M |
| 2023-12-31 | $630.02M |
| 2023-09-30 | $353.91M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.